Intriguingly, DMBA + ROSI-treated PPARγ-MG KO mammary tumours exhibited a significant ~4-fold increase in Cox-2 compared to DMBA Only-treated PPARγ-MG KOs (p < 0.01), as well as a significant ~3-fold increase in Cox-2 compared to DMBA + ROSI-treated PPARγ-WT mice (p < 0.01). This evidence concerns the gene PPARG and breast cancer.